50892-23-4 Usage
Uses
Used in Pharmaceutical Research:
WY-14643 is used as a highly potent PPARα agonist for various pharmaceutical research applications, including the study of its anti-inflammatory properties and its effects on adipocyte browning and amyloid precursor protein proteolysis.
Used in Transfection and Luciferase Assay:
WY-14643 serves as a positive control in transfection and luciferase assays, helping researchers evaluate the efficiency of gene delivery and expression in various cell types.
Used in Autophagic Flux Analysis:
In the field of cell biology, WY-14643 is used to stimulate bone marrow-derived macrophages (BMDM) for autophagic flux analysis, providing insights into the regulation of autophagy and its role in cellular processes.
Used in Fatty Acid Metabolism-Immune Nexus (FAMIN) Expression Analysis:
WY-14643 is utilized in cell culture to analyze the regulation of FAMIN expression, contributing to the understanding of the interplay between fatty acid metabolism and immune responses.
Biological Activity
Selective PPAR α agonist (EC 50 values are 0.63, 32 and > 100 μ M at PPAR α , PPAR γ and PPAR δ respectively). Negatively inhibits NF- κ B transcriptional activity and decreases the inflammatory response in vitro and in vivo .
Biochem/physiol Actions
Selective PPARα agonist.
Safety Profile
Moderately toxic by
ingestion. Suspected carcinogen with
experimental carcinogenic and tumorigenic
data. Mutation data reported. When heated
to decomposition it emits very toxic fumes
of Cl-, NOx and SOx
References
1) Forman et al. (1997), Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta; Proc. Natl. Acad. Sci. USA, 94 4312
2) Devchand et al. (1996), The PPARalpha-leukotriene B4 pathway to inflammation control; Nature, 384 39
3) Heckler et al. (2015), PPAR-a activation reduced LPS-induced inflammation in alveolar epithelial cells; Exp. Lung Res., 41 393
4) Wang et al. (2015), WY14643 combined with all-trans retinoic acid acts via p38 MAPK to induce “browning” of white adipocytes in mice; Genet. Mol. Res., 14 6978
5) Corbett et al. (2015), Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP; Proc. Natl. Acad. Sci. USA, 112 8445
6) Merk et al. (2015), Pirinixic acids: flexible fatty acid mimetics with various biological activities; Future Med. Chem., 7 1597
Check Digit Verification of cas no
The CAS Registry Mumber 50892-23-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,8,9 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 50892-23:
(7*5)+(6*0)+(5*8)+(4*9)+(3*2)+(2*2)+(1*3)=124
124 % 10 = 4
So 50892-23-4 is a valid CAS Registry Number.
InChI:InChI=1/C14H14ClN3O2S/c1-8-4-3-5-10(9(8)2)16-12-6-11(15)17-14(18-12)21-7-13(19)20/h3-6H,7H2,1-2H3,(H,19,20)(H,16,17,18)
50892-23-4Relevant academic research and scientific papers
Treatment of skin conditions by use of PPAR alpha activators
-
, (2008/06/13)
Disorders of the skin and mucous membrane that have a disrupted or dysfunctional epidermal barrier are treated or prevented by topical application of compounds that are either activators of the farnesoid X receptor, activators of the peroxisome proliferator-activated receptor alpha , and oxysterol activators of the LXR alpha receptor. The same compounds are also effective in treating disorders of epidermal differentiation and proliferation.
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents
d'Atri,Gomarasca,Resnati,Tronconi,Scolastico,Sirtori
, p. 1621 - 1629 (2007/10/02)
New compounds were synthesized by changing the substituents of a trisubstituted pyrimidine, i.e., [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid, a potent hypolipidemic agent, impaired, however, by a marked hepatomegaly-inducing effect. The structural variations led to the subsidence (14b, i.e., 4-chloro-2-(dimethylamino)-6-[(2,3-dimethylphenyl)amino]pyrimidine) or to the reduction (18b, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]amino]acetic acid) of said untoward effect but still maintained the hypolipidemic effect that, although markedly decreased, still proves significant for serum cholesterol and triglycerides (18b) or for serum triglycerides only (14b).
2-PYRIMIDINYLTHIO)ALKANOIC ACIDS, ESTERS, AMIDES AND HYDRAZIDES
-
, (2008/06/13)
(2-Pyrimidinylthio)alkanoic acid, esters, amides and hydrazides as well as various 4- and 6-substituted derivatives thereof as depicted by the structural formula: SPC1 In which R and R2 are independently --H or lower alkyl; R1 is --H
